Prosecution Insights
Last updated: April 19, 2026
Application No. 17/420,007

PYRROLOBENZODIAZEPINE DIMER COMPOUND WITH IMPROVED SAFETY AND USE THEREOF

Final Rejection §102
Filed
Jun 30, 2021
Examiner
PECKHAM, RICHARD GRANT
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Legochem Biosciences Inc.
OA Round
2 (Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
80 granted / 117 resolved
+8.4% vs TC avg
Strong +35% interview lift
Without
With
+35.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
42 currently pending
Career history
159
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
29.3%
-10.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 117 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment The amendment filed 10/24/2025 has been entered. Newly amended Claims 1-7 and 9-30 are pending in the application. Applicant’s amendments to the Claims have overcome every objection and rejection previously set forth in the Non-Final Office Action mailed 7/25/2025. Claims 10-30 are withdrawn. Claims 1-7 and 9 are examined on the merits herein. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied and constitute the complete set presently being applied to the instant application. Claim Objections Claims 1-4 and 6-7 are objected to because of the following informalities: Hydrogen is referred to as both “H” and “hydrogen” throughout the cited claims. It is requested that the term used to refer to said group be standardized. Appropriate correction is required. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-7 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Bouchard (WO2009016516, published 2/05/2009). Bouchard teaches the following dimeric compounds (Page 51, Scheme 3): PNG media_image1.png 119 310 media_image1.png Greyscale PNG media_image2.png 123 357 media_image2.png Greyscale , in which the following definitions of Chem. I apply: R1 and R1’ are each =CH2; R2, R2’, R3, R3’, R5, R5’, R7, and R7’ are each hydrogen; R4 and R4’ are each methoxy; Y and Y’ are each -O-; and R6 is PNG media_image3.png 30 112 media_image3.png Greyscale , wherein A is 1-propyl-3,5-dimethyl-phenyl, B1 is -O-, B2 is –((CH2)pV)q- wherein V is -O-, p is 2, and q is 4, and C is RqC(O)ORr, wherein Rq is C1 alkylene and Rr is C1alkyl or hydrogen. Conclusion No claim is allowable. Claim 9 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Applicant’s amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Inquiries Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard G. Peckham whose telephone number is (703)756-4621. The examiner can normally be reached 7:30am - 4:30pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kortney Klinkel can be reached on (571) 270-5239. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /RICHARD GRANT PECKHAM/Examiner, Art Unit 1627 /Kortney L. Klinkel/Supervisory Patent Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Jun 30, 2021
Application Filed
Jun 30, 2021
Response after Non-Final Action
Jul 16, 2025
Non-Final Rejection — §102
Oct 24, 2025
Response Filed
Nov 24, 2025
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595243
MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE
2y 5m to grant Granted Apr 07, 2026
Patent 12583859
PRMT5 INHIBITORS AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583823
CRYSTAL FORM OF DAPRODUSTAT, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570614
Phenyl Amino Pyrimidine Compounds and Uses Thereof
2y 5m to grant Granted Mar 10, 2026
Patent 12569452
OPTHALMIC COMPOSITIONS COMPRISING F6H8
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+35.3%)
3y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 117 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month